• About us
• Contact

Advertisement

Organisation › Details

Probiodrug AG (Euronext Amsterdam: PBD)

Headquartered in Halle, Germany, Probiodrug AG (Euronext Amsterdam: PBD) is a biopharmaceutical company focused on the development of new therapeutic products for the treatment of Alzheimer’s disease. Founded in 1997, the company successfully developed a novel therapeutic concept for diabetes – the DP4 inhibitors – which provided the basis for a novel class of antidiabetics – the gliptins. Its core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes involved in the modification of proteins and peptides, which play a central role in pathological conditions. Today Probiodrug’s aim is to become a leading company in the development of Alzheimer’s disease treatments and to thereby provide a better life for Alzheimer’s disease patients. It has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight Alzheimer’s disease. The Company has medical use and composition of matter patents related to the inhibition of Glutaminyl Cyclase (QC) and anti-pGlu-Abeta- specific monoclonal antibodies, providing it, in the Company’s view, with a leading position in this field of research. *

 

	Start	1997-06-01 established_pre
	End	2019-06-11 renamed
	Group	Vivoryon (Group)
	Today	Vivoryon Therapeutics AG (Euronext Amsterdam: VVY)
	Predecessor	Probiodrug Gesellschaft für Arzneimittelforschung mbH
	Successor	Vivoryon Therapeutics AG (Euronext Amsterdam: VVY)
	Industry	drug development technology
	Region	Halle (Saale)
	Country	Germany
	Street	22 Weinbergweg
	City	06120 Halle (Saale)
	Tel	+49-345-55599-00
		Address record changed: 2020-12-02
Basic data	Employees	B: 11 to 50 (2016-12-31)
	Currency	EUR
	Annual sales	44,000 (operating income (2015) 2015-12-31)
	Profit	-13,891,000 (2016-12-31)
	Cash	9,300,000 (2018-03-31)
		* Document for »About Section«:
		Record changed: 2024-12-29

Advertisement

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.